Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DFS
Discover Financial Services
DFS
|
+$580M |
| 2 |
Autodesk
ADSK
|
+$544M |
| 3 |
McKesson
MCK
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$288M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$275M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$508M |
| 2 |
Salesforce
CRM
|
+$266M |
| 3 |
ServiceNow
NOW
|
+$264M |
| 4 |
S&P Global
SPGI
|
+$246M |
| 5 |
Sherwin-Williams
SHW
|
+$212M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.98% |
| 2 | Technology | 14.71% |
| 3 | Financials | 12.17% |
| 4 | Communication Services | 7.05% |
| 5 | Industrials | 4.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Glaukos
GKOS
$10.9B
| $390K | ﹤0.01% |
2,600
| – | – |
|
102
BrightSpring Health Services
BTSG
$11.6B
| $375K | ﹤0.01% |
22,000
| – | – |
|
103
Arcutis Biotherapeutics
ARQT
$3.15B
| $362K | ﹤0.01% |
26,000
| – | – |
|
104
Twist Bioscience
TWST
$9.13B
| $355K | ﹤0.01% |
7,650
-333,000
| -98% | -$15M |
|
105
United Therapeutics
UTHR
$22B
| $353K | ﹤0.01% |
1,000
| – | – |
|
|
BPMC
106
DELISTED
Blueprint Medicines
BPMC
| $349K | ﹤0.01% |
4,000
| – | – |
|
107
Axsome Therapeutics
AXSM
$10.9B
| $338K | ﹤0.01% |
4,000
| – | – |
|
108
Krystal Biotech
KRYS
$10.3B
| $313K | ﹤0.01% |
2,000
| – | – |
|
109
Progyny
PGNY
$1.97B
| $311K | ﹤0.01% |
18,000
-913,307
| -98% | -$14.2M |
|
|
ACLX
110
DELISTED
Arcellx
ACLX
| $307K | ﹤0.01% |
4,000
| – | – |
|
111
Scholar Rock
SRRK
$6.88B
| $303K | ﹤0.01% |
+7,000
| New | +$228K |
|
112
HCA Healthcare
HCA
$92.9B
| $300K | ﹤0.01% |
1,000
| – | – |
|
113
Globus Medical
GMED
$11.7B
| $298K | ﹤0.01% |
3,600
| – | – |
|
114
Immunovant
IMVT
$9.16B
| $297K | ﹤0.01% |
12,000
| – | – |
|
115
Bruker
BRKR
$9.07B
| $293K | ﹤0.01% |
5,000
-27,000
| -84% | -$1.6M |
|
116
Merit Medical Systems
MMSI
$5.42B
| $290K | ﹤0.01% |
3,000
| – | – |
|
117
HealthEquity
HQY
$8.81B
| $269K | ﹤0.01% |
2,800
| – | – |
|
118
Pacific Biosciences
PACB
$420M
| $247K | ﹤0.01% |
135,000
| – | – |
|
119
Sabra Healthcare REIT
SBRA
$5.21B
| $242K | ﹤0.01% |
14,000
| – | – |
|
|
SAGE
120
DELISTED
Sage Therapeutics
SAGE
| $232K | ﹤0.01% |
42,800
| – | – |
|
121
Cencora
COR
$60.7B
| $225K | ﹤0.01% |
1,000
-234,200
| -100% | -$55.1M |
|
122
Edwards Lifesciences
EW
$51.8B
| $222K | ﹤0.01% |
+3,000
| New | +$210K |
|
123
ICU Medical
ICUI
$4.57B
| $217K | ﹤0.01% |
1,400
| – | – |
|
124
Chemed
CHE
$7.07B
| $212K | ﹤0.01% |
400
| – | – |
|
125
Icon
ICLR
$13.3B
| $210K | ﹤0.01% |
1,000
-219,800
| -100% | -$51.3M |
|
Similar funds
Thomas Steyer's Q4 2024 Portfolio in Review
As of Q4 2024, Thomas Steyer held 188 positions worth $22.8B, down 0.02% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Thomas Steyer's Q4 2024 filing shows 24 new, 37 increased, 34 reduced and 37 closed positions. Its largest new stake was Autodesk: 1,841,800 shares worth $544M. The largest sale was CATALENT, INC., an estimated $508M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 32% a quarter earlier, followed by Technology and Financials.
- Thomas Steyer's largest Q4 2024 buy was Autodesk: 1,841,800 shares worth $544M.
- Thomas Steyer added most to Discover Financial Services in Q4 2024, an estimated $580M increase.
- Thomas Steyer's biggest Q4 2024 reduction was Salesforce, cutting an estimated $266M.
- Thomas Steyer fully exited CATALENT, INC. in Q4 2024, selling an estimated $508M.
- Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q4 2024.
- Thomas Steyer opened 24 new positions and closed 37 in Q4 2024.
- Thomas Steyer's portfolio value fell 0.02% quarter-over-quarter to $22.8B.
Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.